Document Detail

Effect of dialysis modality on survival of hepatitis C-infected ESRF patients.
MedLine Citation:
PMID:  21903989     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVES: Hepatitis C virus (HCV) infection is associated with increased mortality and morbidity in end-stage renal failure (ESRF) patients. Despite a lower incidence and risk of transmission of HCV infection with peritoneal dialysis (PD), the optimal dialysis modality for HCV-infected ESRF patients is not known. The aim of this study was to evaluate the impact of dialysis modality on the survival of HCV-infected ESRF patients.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included all adult incident ESRF patients in Australia and New Zealand who commenced dialysis between January 1, 1994, and December 31, 2008, and were HCV antibody-positive at the time of dialysis commencement. Time to all-cause mortality was compared between hemodialysis (HD) and PD according to modality assignment at day 90, using Cox proportional hazards model analysis.
RESULTS: A total of 424 HCV-infected ESRF patients commenced dialysis during the study period and survived for at least 90 days (PD n = 134; HD n = 290). Mortality rates were comparable between PD and HD in the first year (10.7 versus 13.8 deaths per 100 patient-years, respectively; adjusted hazard ratio [HR] 0.65, 95% CI 0.34 to 1.26) and thereafter (20 versus 15.9 deaths per 100 patient-years, respectively; HR 1.27, 95% CI 0.86 to 1.88).
CONCLUSIONS: The survival of HCV-infected ESRF patients is comparable between PD and HD.
Bhadran Bose; Stephen P McDonald; Carmel M Hawley; Fiona G Brown; Sunil V Badve; Kathryn J Wiggins; Kym M Bannister; Neil Boudville; Philip Clayton; David W Johnson
Related Documents :
25191049 - A hospital-based retrospective study on frequency and distribution of viral hepatitis.
25493019 - Applicability and efficacy of a model for prevention of perinatal transmission of hepat...
20545439 - Properties of hepatitis c virus minigenome containing mutated 5'utr region and lucifera...
25300999 - Impact of alloimmune t cell responses on hepatitis c virus replication in liver transpl...
17604129 - A replicon-based shuttle vector system for assessing the phenotype of hcv ns5b polymera...
8995709 - Structure of replicating hepatitis c virus (hcv) quasispecies in the liver may not be r...
22819659 - Successes and challenges of hiv prevention in men who have sex with men.
12162409 - Severe manifestation of acute hepatitis a recently found in gunma, japan.
14729929 - Lack of circulating candida mannoprotein antigen in patients with focal hepatosplenic c...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study     Date:  2011-09-08
Journal Detail:
Title:  Clinical journal of the American Society of Nephrology : CJASN     Volume:  6     ISSN:  1555-905X     ISO Abbreviation:  Clin J Am Soc Nephrol     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-09     Completed Date:  2012-02-29     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  101271570     Medline TA:  Clin J Am Soc Nephrol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2657-61     Citation Subset:  IM    
Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Australia / epidemiology
Biological Markers / blood
Chi-Square Distribution
Hepatitis C / diagnosis,  mortality*
Hepatitis C Antibodies / blood
Kidney Failure, Chronic / mortality*,  therapy*
Middle Aged
New Zealand
Peritoneal Dialysis / mortality*
Proportional Hazards Models
Renal Dialysis / mortality*
Retrospective Studies
Risk Assessment
Risk Factors
Survival Analysis
Survival Rate
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Biological Markers; 0/Hepatitis C Antibodies

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus.
Next Document:  Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.